Approximately 25% of all cancers diagnosed each year are rare cancers. Despite this, the five-year survival rate for rare cancer patients is much lower than for those with non-rare cancers. This is why the Case Comprehensive Cancer Center (Case CCC) is kickstarting CURE (Conducting Unprecedented Research and Exploration): The Rare Cancer Initiative. Led by Case CCC Director Gary Schwartz, MD, the initiative builds on Case CCC’s collaborative nature, creating a national network among U.S. cancer centers and catalyzing innovative bench-to-bedside approaches to identify, treat, and, ultimately, defeat rare cancers.
Our goal is to raise $1 million a year for CURE in partnership with the —an organization founded by Mark and Linda Taxel in memory of their son Jed, who died from a rare cancer just six months after his diagnosis. CURE will fund cutting-edge research and therapies at Case CCC. We hope you will join the crusade to conquer rare cancer.
Together, we can transform cancer research and save lives worldwide.